Sofinnova Investments and Novo Holdings led a $165m Series A round in Expedition Therapeutics.

Sofinnova Investments, a healthcare investment firm, and Novo Holdings, a holding and investment company, led a $165m Series A round in Expedition Therapeutics, a biotechnology company developing novel therapies for serious inflammatory and respiratory diseases, with participation from Forbion, KKR) Adage, Balyasny, Logos Capital, Sanofi Ventures, BVF Partners and Venrock Healthcare Capital Partners. “Most COPD patients lack effective treatment options. DPP1 represents an exciting new mechanism for COPD, and EXPD-101 has the potential to be a first-in-class therapy with this target. This financing from top-tier investors allows us to accelerate development, with the potential to treat a broad range of COPD patients, addressing a major unmet need and improving the standard of care for millions. Beyond COPD, EXPD-101 also has first/best-in-class potential to address a broad spectrum of other neutrophil-driven diseases in the future,” Yi Larson, Expedition Therapeutics Founder and CEO.